BioSpace News Archive

Genetown

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced a strategic pipeline update and outlined its expected upcoming milestones.

January 10, 2022
·
8 min read
Drug Development

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio announced the first patient has been dosed in the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy.

January 10, 2022
·
6 min read
Business

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

Amarin Corporation plc provided a business update, including preliminary unaudited full-year 2021 revenue results.

January 10, 2022
·
22 min read
XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10th through 13th, 2022.

January 10, 2022
·
2 min read
Business

Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million

Invitae Corporation, a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022.

January 10, 2022
·
5 min read
Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease

Calon Cardio-Technology Ltd. and Leviticus-Cardio Ltd. announce the joint Development and Testing of a Wireless, Fully Implantable, Long-Term Blood Pump.

January 10, 2022
·
5 min read
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

SHERBROOKE, QC, Jan. 10, 2022 /PRNewswire/ - Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays.

January 10, 2022
·
3 min read
Business

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

Omega Therapeutics, Inc. announced the appointment of Yan Moore, M.D., as Chief Medical Officer.

January 10, 2022
·
7 min read
Business

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results

Castle Biosciences, Inc. today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2021.

January 10, 2022
·
7 min read
Business

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results

STAAR Surgical Company today provided preliminary results for the fourth quarter and fiscal year ended December 31, 2021.

January 10, 2022
·
5 min read